By John Philpott – Stockwatch – December 22, 2017
CANABO MEDICAL INC. ANNOUNCES PROPOSED BUSINESS COMBINATION WITH ALEAFIA INC.
Canabo Medical Inc. has entered into a letter of intent dated Dec. 22, 2017, relating to a proposed business combination with Aleafia Inc., a private corporation existing under the laws of Ontario, with its operations and head office in Concord, Ont.
Overview of Aleafia
Aleafia operates the Aleafia Total Health network in Vaughan, Ont. Aleafia seeks to make a difference in cannabinoid therapy delivery by providing an interconnected medical service model. While most clinical programs are geared primarily toward postinjury rehabilitation, the Aleafia network is focused on the strong link between early intervention and successful treatment. The intent is to manage health through a patient-focused, assessment-based and interdisciplinary-resourced organization.
Recently, Aleafia completed a transaction under which it acquired 100 per cent of the issued and outstanding shares of 755064 Ontario Inc. (operating as AeroFarms Canada), a licensed producer under the Health Canada Access to Cannabis for Medical Purposes Regulations (ACMPR), as well as the land and building in Scugog, Ont., where the facility operates. Aleafia acquired AeroFarms Canada to directly support the Aleafia network.
The proposed transaction
Pursuant to the terms of the proposed transaction, Canabo will acquire all of the issued securities of Aleafia, and, in consideration, subject to the acceptance of the TSX Venture Exchange, the company will issue approximately 73.67 million common shares to the former shareholders of Aleafia and five million stock options to the former optionholders of Aleafia on a one-for-one basis. After completion of the proposed transaction and completion of the Aleafia private placement (as defined below), the resulting issuer will be named Aleafia Group Inc., or such other name as may be acceptable to Aleafia, the TSX-V and regulatory authorities. After completion of the proposed transaction, the shareholders of the company will hold approximately 29.7 per cent of the issued common shares of the resulting issuer, the former shareholders of Aleafia will hold approximately 57.8 per cent of the resulting issuer shares, and shareholders who purchase in the Aleafia private placement (as defined below) will hold approximately 12.5 per cent (not including the overallotment option (as defined below)) of the resulting issuer shares, on a non-diluted basis.
This proposed transaction may be effected through either an exchange of securities, three-cornered amalgamation, plan of arrangement or other structure, following receipt of legal, financial and tax advice by the parties.
The company currently has 37,962,461 common shares issued and outstanding, or approximately 39,930,811 common shares on a fully diluted basis.
Concurrently with the proposed transaction, Aleafia intends to complete a brokered private placement of subscription receipts on a best-efforts basis for gross proceeds of approximately $20-million at an offering price of $1.25 per subscription receipt. The agents (as defined below) will have the option exercisable any time up to 24 hours prior to the closing of the offering to increase the size of the Aleafia private placement by up to 15 per cent for a total offering size of up to $23-million. Each subscription receipt will, following the completion of the Aleafia private placement and the satisfaction of certain escrow release conditions, entitle the holder to receive, without payment of additional consideration or taking of further action, one unit consisting of one common share and one-half of one common share purchase warrant in the capital of the resulting issuer. Each whole warrant is exercisable into one common share in the resulting issuer at a price of $1.75 for 18 months following issuance.
Mackie Research Capital Corp. will be a lead agent and sole bookrunner for the Aleafia private placement, and may invite other registered investment dealers to participate in a selling syndicate. The agents shall receive a cash commission equal to 6.0 per cent (excluding the gross proceeds raised from investors on the president’s list (as defined below) for which there will be a 3-per-cent commission) and will be issued compensation options to purchase the number of common shares of the resulting issuer equal to 6.0 per cent of the number of subscription receipts sold at a price of $1.25 for a period of 18 months from the closing date of the Aleafia private placement. Aleafia will provide the agents with a list of eligible purchasers for up to a maximum of $5-million (or $5.75-million if the overallotment option is exercised), together with an allocation for such purchasers, which allocation may only be varied upon Aleafia’s agreement.
On the private placement closing date, the gross proceeds from the Aleafia private placement, less any agents’ expenses incurred up to and including the private placement closing date, will be deposited into escrow, pending completion of the proposed transaction. If for any reason the proposed transaction does not close, then the proceeds will be refunded to the subscribers without penalty or deduction.
Upon completion of the proposed transaction, it is expected that the resulting issuer will meet the listing requirements of an exchange Tier 2 life sciences issuer.
The completion of the proposed transaction will be subject to certain mutual conditions precedent, including:
The satisfaction of each party with the results of its due diligence investigation of the other;
The execution of a definitive agreement;
The approval of all matters and documentation in support of the proposed transaction;
The receipt of any and all necessary regulatory, corporate and third party approvals, including the acceptance of the exchange, and compliance with all applicable regulatory requirements and conditions in connection with the proposed transaction;
The completion of the Aleafia private placement;
The maintenance of Canabo’s listing on the exchange;
The confirmation of the representations and warranties of each party to the definitive agreement as set out in such agreement;
The delivery of standard completion documentation;
Other conditions precedent customary for a transaction similar to the proposed transaction.
The conditions precedent in favour of the company may be waived in whole or in part by the company, and the conditions precedent in favour of Aleafia may be waived in whole or in part by Aleafia.
The completion of the proposed transaction is expected to occur on the day that is the seventh business day following the satisfaction or waiver of the conditions precedent, or such other date as mutually agreed to by the company and Aleafia, but in any event no later than March 30, 2018. Each of the company and Aleafia will bear its own respective costs and expenses associated with the proposed transaction.
Overview of management and the board of directors
It is expected that the management of the resulting issuer will consist of Julian Fantino as executive chairman, Raf Souccar as president and chief executive officer, Garry Stewart as chief financial officer and corporate secretary, and John Philpott as executive vice-president of clinic operations.
Julian Fantino, PC, COM, OOnt, executive chairman, has had a distinguished career in law enforcement and government, as the chief of the Toronto, York and London police departments, commissioner of emergency management of Ontario, culminating in his appointment as the commissioner of the Ontario Provincial Police. Shortly thereafter, Mr. Fantino was elected as a member of Parliament for the riding of Vaughan. During his time in the House of Commons, Mr. Fantino served as the Minister of Veterans Affairs, Associate Minister of National Defence and Minister for International Cooperation. Mr. Fantino is a leading expert on drug enforcement, federal regulatory policy and an advocate for the well-being of Canada’s posttraumatic stress disorder population.
Raf Souccar, LLB, OOM, president and chief executive officer of Aleafia, served in the Royal Canadian Mounted Police for 34 years in progressively senior roles, retiring as deputy commissioner of federal and international policing. Among his many responsibilities, Mr. Souccar was responsible for drugs and organized crime enforcement, national security, counterterrorism, and the Prime Minister’s security. Since 2004, Mr. Souccar has emerged as a leading expert on cannabis legalization through his global travel and study of foreign public policy measures, and his counsel provided to successive ministers of justice. In 2016, Prime Minister Justin Trudeau appointed Mr. Souccar to the federal government’s nine-member marijuana legalization task force, which provided a final set of public recommendations on legalization. Mr. Souccar is a member of the Canadian Association of Chiefs of Police and the Law Society of Upper Canada, and has served as a member of the International Bar Association and the American Society for Industrial Security. Mr. Souccar also has extensive board and committee experience at the national and international levels. He has held executive positions with the Canadian Association of Chiefs of Police, and has been a member of both the International Association of Chiefs of Police and Interpol.
Garry Stewart, CPA, CA, chief financial officer and secretary of Canabo, has enjoyed a 30-year career in accounting with a focus on financial reporting, operational efficiencies and cash optimization. Garry Stewart has experience with both public and private companies. Most recently, Garry Stewart served as the CFO and vice-president, finance, for a privately held group of companies, TAR Investments Ltd., including Atlantic Business Interiors Ltd. and Datarite Ltd. Garry Stewart graduated with a bachelor of business administration degree from Acadia University, and obtained his CPA and CMA designations in 1990. He was awarded the FCPA and FCMA designations in 2009, and is a member of CPA Nova Scotia and CPA Canada.
John Philpott, executive vice-president of clinic operations, graduated from Memorial University with a bachelor in mechanical engineering in 1995, after completing a three-year petroleum engineering technology program at the Cabot Institute of Applied Engineer Science. Mr. Philpott previously worked as an engineer in Canada, the United States and overseas before founding CanAm Physician Recruiting Inc. in 1997. Mr. Philpott has now been active in the medical industry for the past two decades, serving as the CEO of a leading North American physician recruitment firm. In 2013, Mr. Philpott became a member of Canadian management consultant and is certified through the executive stream. He is an active volunteer, and serves on numerous boards and executive committees, including the Halifax Club (the oldest business club in North America), East Hants Sportsplex, and Oakfield Golf & Country Club.
Board of directors
It is the intention of the company and Aleafia to establish and maintain a board of directors of the resulting issuer with a combination of appropriate skill sets that is compliant with all regulatory and corporate governance requirements, including any applicable independence requirements. Upon completion of the proposed transaction, the board of the resulting issuer is expected to comprise seven individuals, which will include two members of the current board of the company, to be named prior to the closing of the proposed transaction, and five nominees of Aleafia. The nominees of Aleafia are expected to be Mr. Fantino, Mr. Souccar, William Stewart and Dr. Gary Goodyear. The final nominee of Aleafia will be announced prior to the closing of the proposed transaction.
William Stewart, director, has had a distinguished career as a fire services leader. Following nearly 40 years of active duty, William Stewart was appointed as the chief of the Toronto Fire Services in 2003. William Stewart served in this role until 2012, and was named Fire Chief of the Year in 2008 and 2010 by the Canadian Association of Fire Chiefs. William Stewart currently serves on the boards of the National Fire Protection Association and the Canadian Fallen Fire Fighters Association. Prior to his career in the fire services, William Stewart was a commissioned officer of the Canadian Armed Force Reserve.
Dr. Gary Goodyear, PC, director, served a member of Parliament from 2004 to 2015, for the riding of Cambridge. During his time in the House of Commons, Dr. Goodyear served as the Minister of State for Science and Technology and as the Minister of State responsible for the Federal Economic Development Agency for Southern Ontario. Prior to serving as a member of Parliament, Dr. Goodyear was a doctor of chiropractic for 20 years, where he practised as the clinic director, director of patient services and past president of future recovery, Canada.
About Canabo Medical Inc.
Canabo wholly owns and operates Cannabinoid Medical Clinics, or CMClinics, Canada’s largest physician-led referral-only clinics for medical cannabis. Established in 2014, Canabo now has 19 clinics across Canada, with additional locations planned to open in 2017. Canabo operates referral-only medical clinics dedicated to evaluating the suitability of prescribing and monitoring cannabinoid treatments for patients suffering from chronic pain and disabling illnesses. Clinics operated by Canabo are staffed by physicians and qualified health care practitioners specifically trained to assess patient suitability for cannabinoid treatment, recommend treatment regimes and monitor treatment progress.
In accordance with exchange policy, the company’s shares are currently halted from trading and are expected to remain halted until after the exchange has reviewed the materials in support of the proposed transaction.
We seek Safe Harbor.
© 2018 Canjex Publishing Ltd. All rights reserved.